|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
In summary, we identified a competition for binding the 69-nt sequence, through which vigilin and HuR exert opposing effects on c-fms expression, suggesting a role for vigilin in suppression of breast cancer progression.
|
20974809 |
2011 |
|
Malignant neoplasm of breast
|
0.330 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
Vigilin, a nucleocytoplasmic shuttling protein, post-transcriptionally suppresses proto-oncogene c-fms expression (encoding CSF-1R) in breast cancer by binding to a 69 nt cis-acting 3-UTR element in CSF-1R mRNA.
|
30292064 |
2019 |
|
Malignant neoplasm of breast
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Multidimensional analysis of microarray datasets demonstrated up-regulation of genes encoding HBP enzymes in clinical breast cancers and revealed that co-expression of hyaluronan synthase 2 (HAS2) and glutamine:fructose-6-phosphate amidotransferase (GFAT), a rate-limiting enzyme of the HBP, was strongly correlated with a poor prognosis in advanced cancer patients.
|
31645543 |
2019 |
|
Autistic Disorder
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
FARP2, HDLBP and PASK are downregulated in a patient with autism and 2q37.3 deletion syndrome.
|
19365831 |
2009 |
|
Autistic Disorder
|
0.310 |
Biomarker
|
disease |
CTD_human |
FARP2, HDLBP and PASK are downregulated in a patient with autism and 2q37.3 deletion syndrome.
|
19365831 |
2009 |
|
Chromosome 2q37 deletion syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
FARP2, HDLBP and PASK are downregulated in a patient with autism and 2q37.3 deletion syndrome.
|
19365831 |
2009 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia.
|
23770605 |
2013 |
|
Chronic Lymphocytic Leukemia
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia.
|
26956414 |
2016 |
|
Small Lymphocytic Lymphoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia.
|
26956414 |
2016 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.050 |
Biomarker
|
disease |
BEFREE |
Maximum home blood pressure is a useful indicator of diabetic nephropathy in patients with type 2 diabetes mellitus: KAMOGAWA-HBP study.
|
28819987 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.050 |
Biomarker
|
disease |
BEFREE |
Impact of masked hypertension on diabetic nephropathy in patients with type II diabetes: a KAMOGAWA-HBP study.
|
29548933 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.050 |
Biomarker
|
disease |
BEFREE |
Threshold value of home pulse pressure predicting arterial stiffness in patients with type 2 diabetes: KAMOGAWA-HBP study.
|
29447439 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.050 |
Biomarker
|
disease |
BEFREE |
Home blood pressure is associated with cognitive impairment among elderly patients with type 2 diabetes: KAMOGAWA-HBP study.
|
31081363 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.050 |
Biomarker
|
disease |
BEFREE |
Isolated high home systolic blood pressure in patients with type 2 diabetes is a prognostic factor for the development of diabetic nephropathy: KAMOGAWA-HBP study.
|
31711859 |
2019 |
|
Diabetic Nephropathy
|
0.050 |
Biomarker
|
disease |
BEFREE |
Impact of masked hypertension on diabetic nephropathy in patients with type II diabetes: a KAMOGAWA-HBP study.
|
29548933 |
2018 |
|
Diabetic Nephropathy
|
0.050 |
Biomarker
|
disease |
BEFREE |
Maximum home blood pressure is a useful indicator of diabetic nephropathy in patients with type 2 diabetes mellitus: KAMOGAWA-HBP study.
|
28819987 |
2017 |
|
Diabetic Nephropathy
|
0.050 |
Biomarker
|
disease |
BEFREE |
Maximum morning home systolic blood pressure is an indicator of the development of diabetic nephropathy: The KAMOGAWA-HBP study.
|
30884176 |
2019 |
|
Diabetic Nephropathy
|
0.050 |
Biomarker
|
disease |
BEFREE |
Prognostic significance of home pulse pressure for progression of diabetic nephropathy: KAMOGAWA-HBP study.
|
29540826 |
2018 |
|
Diabetic Nephropathy
|
0.050 |
Biomarker
|
disease |
BEFREE |
Isolated high home systolic blood pressure in patients with type 2 diabetes is a prognostic factor for the development of diabetic nephropathy: KAMOGAWA-HBP study.
|
31711859 |
2019 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Modifying LI-RADS for use with Gd-EOB-MRI, such as applying HBP hypointensity as an additional major feature or using TP hypointensity as washout appearance, can improve the sensitivity for the detection of HCC.
|
29922928 |
2019 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Contrast-to-noise ratio 2 in the HBP with the cutoff of less than 4.56 could distinguish moderately differentiated HCCs from PD HCC with the sensitivity and specificity of 84.6% and 60.0%, respectively.
|
29369947 |
2018 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest that progressively upregulated vigilin may serve as a molecular risk marker for HCC development, and targeting vigilin may help to inhibit HCC cell growth, survival and migration.
|
24676454 |
2014 |
|
Liver carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The expression of vigilin was previously reported to elevate in highly proliferating tissues and increased in a subset of hepatocellular carcinoma patients.
|
26032007 |
2015 |
|
Kidney Failure, Acute
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
HBP levels identified patients with moderate AKI with an area under curve (AUC) of 0.85.
|
28319494 |
2017 |